Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 mars 2025 05h33 HE | Source: Research and Markets

GLP-1 Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Drug Candidates in Development for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom

Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "GLP-1 Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist,...
27 sept. 2024 09h19 HE | Source: Research and Markets

Diabetes Drugs Global Strategic Business Report 2024: Market to Surpass $205 Billion by 2030 - Development of GLP-1 Receptor Agonists Expands Treatment Options

Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Diabetes Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Diabetes Drugs...
13 juin 2023 17h30 HE | Source: Graphical Research

GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI

Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...
01 mars 2023 11h00 HE | Source: FACT.MR

Peptide-based Metabolic Disorders Therapeutics Market to Surpass US$ 77.9 billion by 2033; As Governments Engage in Supportive Initiatives to Spur Healthcare Sector

Rockville, March 01, 2023 (GLOBE NEWSWIRE) -- The peptide-based metabolic disorder therapeutics market analysis offered by Fact.MR highlights key growth-shaping factors inducing demand in the...
26 mai 2021 01h30 HE | Source: Adocia SA

泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域

已申请三项专利系列涵盖新型激素组合：普兰林肽-艾塞那肽和胰高血糖素-艾塞那肽——两种组合在肥胖症治疗中均显示出令人鼓舞的效果通过泵输注短效激素可以增强患者授权，使患者可以优化治疗的获益/风险比这些配方也可以用于治疗其他代谢性疾病，例如NASH（非酒精性脂肪性肝炎），2型糖尿病或神经退行性疾病里昂, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia...
26 mai 2021 01h30 HE | Source: Adocia SA

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...
12 juin 2017 09h00 HE | Source: ProLynx LLC

ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to...